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Abstract
In patients with chronic heart failure, iron deﬁciency, even in the absence of anaemia, can aggravate the underlying disease
and have a negative impact on clinical outcomes and quality of life. The 2016 European Society of Cardiology guidelines for
the diagnosis and treatment of acute and chronic heart failure recognize iron deﬁciency as a co-morbidity in chronic heart fail-
ure and recommend iron status screening in all newly diagnosed patients with chronic heart failure. Furthermore, the guide-
lines speciﬁcally recommend considerations of intravenous iron therapy, ferric carboxymaltose, for the treatment of iron
deﬁciency. However, in spite of these recommendations, iron deﬁciency remains often overlooked and undertreated. This
may be due, in part, to the lack of clinical context and practical guidance accompanying the guidelines for the treating physi-
cian. Here, we provide practical guidance complemented by a case study to assist and improve the timely diagnosis, treat-
ment, and routine management of iron deﬁciency in patients with chronic heart failure.
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Introduction
Iron deﬁciency is a ‘health-related condition in which iron
availability is insufﬁcient to meet the body’s needs and which
can be present with or without anaemia’.1 In chronic heart
failure (CHF), iron deﬁciency is a recognized co-morbidity af-
fecting 37–61% of patients.2–5 The causes of iron deﬁciency
in the CHF setting can be multifactorial, arising from chronic
inﬂammation, decreased iron intake (poor nutrition and loss
of appetite), decreased gastrointestinal (GI) iron absorption
due to oedema, and increased GI blood loss (partially
resulting from antiplatelet and anticoagulant drugs).6,7
Exercise intolerance and fatigue are deﬁning features of
patients with CHF. Studies have shown that iron deﬁciency,
even before the onset of anaemia, can be particularly severe
in patients with CHF, aggravating the underlying disease and
negatively impacting symptoms, quality of life (QoL), exercise
capacity, and clinical outcomes, and has been associated with
an increased risk ofmortality of 40–60%.2–4,8–17 In addition, iron
deﬁciency has been shown to increase the risk of hospitalization
in patients with CHF by two-fold (relative risk 2.23, 95% conﬁ-
dence interval 1.59–3.42; P < 0.001).8 Appropriate treatment
of iron deﬁciency in CHF patients has been shown to alleviate
symptoms and decrease hospitalizations for heart failure.10–15
The 2016 European Society of Cardiology (ESC) guidelines
for the diagnosis and treatment of acute and chronic heart fail-
ure recommend that all newly diagnosed patients with heart
failure are tested for iron deﬁciency.18 Moreover, intravenous
(i.v.) iron, ferric carboxymaltose, is speciﬁcally recommended
in the ESC guidelines to be considered for the treatment of
iron deﬁciency in order to alleviate heart failure symptoms
and improve exercise capacity and QoL.18 Yet, in spite of these
recommendations, iron deﬁciency remains underdiagnosed
and undertreated.19 This may partially be due to the lack of
clinical context accompanying available guidelines for the
treating physician. This review thus aims to provide practical
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guidance, illustrated with a commonly encountered clinical
case study, to help clinicians in the timely diagnosis and
management of iron deﬁciency in patients with CHF.
The clinical case
A 73-year-old female patient was ﬁrst admitted with acutely
decompensated heart failure requiring inotropic support
[New York Heart Association (NYHA) IV]. Echocardiogram
showed left ventricular ejection fraction (LVEF) 22%, dilated
left ventricle (68 mm), and moderate functional mitral regur-
gitation. No signiﬁcant stenosis was observed on coronary an-
giography. Medical history included hyperlipidaemia and
idiopathic dilated cardiomyopathy. Once the patient’s condi-
tion had stabilized, the physician initiated heart failure treat-
ment following ESC guideline recommendations, including
carvedilol 12.5 mg/12 h, enalapril 10 mg/12 h, spironolactone
25 mg/24 h, and furosemide 20 mg/24 h. Ambulatory up-
titration of angiotensin-converting enzyme inhibitors and
beta-blockers was limited because of symptomatic hypoten-
sion. The patient also received education and support from
heart failure nurses prior to discharge.
An initial improvement in functional class to NYHA II was
observed; however, the patient later presented with symp-
tomatic deterioration to NYHA III. The patient required two
consultations and day-case hospital visits to receive diuretic
therapy and an unplanned hospital admission for inotropic
therapy. One month after discharge, the patient’s status
remained as NYHA III. She therefore continued with the
medication previously prescribed at the initial diagnosis.
However, she suffered several episodes of decompensation
of heart failure, which were managed with furosemide but
did not require admission. Up-titration of renin–angioten-
sin–aldosterone blockade and beta-blocker treatment was
limited by symptomatic hypotension.
At a routine follow-up examination, cardiac and respiratory
auscultation was normal. There were no signs of
organomegaly, and LVEF was 30%.
What would be the appropriate next steps in
management?
The earlier illustrates a typical case of non-ischaemic heart
failure with reduced ejection fraction (HFrEF), with recurrent
episodes of heart failure decompensation despite optimal
ﬁrst-line guideline-directed medical therapy. Consideration
of additional heart failure therapy is warranted, including
up-titration of medications to guideline-targeted doses, re-
placement of enalapril with angiotensin receptor/neprilysin
inhibitors, addition of ivabradine, and evaluation for device
therapy. Current ESC heart failure guidelines emphasize the
importance of addressing potential precipitating causes of
decompensation and managing co-morbidities.
Moreover, physicians are recommended to measure iron
parameters in all newly diagnosed heart failure patients
(Class of Recommendation I, Level of Evidence C; Table 1), re-
gardless of haemoglobin (Hb) status.18 A recent practical
guidance consensus by a panel of recognized experts in the
ﬁeld of heart failure, based on the 2016 ESC guidelines, also
recommends evaluation of iron status in patients with
existing CHF, particularly if they are symptomatic, and moni-
toring once a year (Table 1).18
Diagnosis of iron deﬁciency in chronic
heart failure
The clinical case
As there was no resolution of the patient’s NYHA III status,
her serum ferritin, transferrin saturation (TSAT), and Hb levels
were examined during a routine follow-up assessment. Test
results revealed serum ferritin to be 10 μg/L, with TSAT of
11% and Hb levels of 11.2 g/dL.
It is worth noting that the current patient was ﬁrst diag-
nosed in 2010, when guidelines for the timely diagnosis of
iron deﬁciency were not available. If the patient was diag-
nosed today, she would meet the guideline recommenda-
tions for checking iron status as part of the initial work up
in patients with heart failure (Table 1).
How do we interpret these results?
The serum ferritin (<100 μg/L) and TSAT levels (< 20%) in this
patient were diagnostic of iron deﬁciency (Figure 1A, Step 1),
while the Hb level (<12 g/dL) indicated mild anaemia
(Figure 1A, Step 2). Serum ferritin reﬂects total body iron
Table 1 Diagnosis of iron deﬁciency in CHF: summary of ESC and
practical guideline recommendations18
In whom and when?
1. Diagnostic workup is recommended/should be considered
for all newly diagnosed heart failure patients (Class of
Recommendation I, Level of Evidence C).
2. Iron status evaluation is also recommended in patients with
existing CHF, particularly if they are symptomatic.
3. Iron parameters should be evaluated at least once a year.
Which parameters should be assessed?
Parameter Threshold
Hb Anaemia: 12 g/dL (women) and 13 g/dL (men)
Serum
ferritin
Iron deﬁciency: <100 μg/L; if between 100 and
<300 μg/L, TSAT results are required to conﬁrm
iron deﬁciency
TSAT Iron deﬁciency: < 20%
CHF, chronic heart failure; ESC, European Society of Cardiology;
Hb, haemoglobin; TSAT, transferrin saturation.
Parameters should be assessed simultaneously.
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stores, and low levels (<100 μg/L in heart failure patients)
are highly speciﬁc for absolute iron deﬁciency (Table 2).6
Therefore, this patient unequivocally had absolute iron deﬁ-
ciency whereby total body iron stores are depleted and may
occur with iron homeostasis mechanisms and erythropoiesis
still intact.6,21
It is critical, however, to recognize that functional iron de-
ﬁciency can be present even if serum ferritin levels are
seemingly normal or even elevated. This is because serum
ferritin is an acute-phase reactant that reﬂects the inﬂam-
matory milieu of heart failure.25 Furthermore, chronic
kidney disease, another chronic inﬂammatory condition, is
highly prevalent in patients with CHF.26 The patient in this
case study had an estimated glomerular ﬁltration rate of
51 mL/min/1.73 m2 suggesting mild to moderate loss of
renal function (chronic kidney disease Stage 3).27 Notably,
laboratory results commonly also report reference values
for serum ferritin and TSAT as measured in patients without
inﬂammation. It is therefore important to understand that
these reference values do not apply to patients with heart
failure, who are characterized by latent inﬂammation.
Functional iron deﬁciency is due to inadequate transport
Figure 1 (A) Diagnostic and (B) treatment algorithms for iron deﬁciency in patients with chronic heart failure.1 *The use of ferric carboxymaltose has
not been studied in children and is therefore not recommended in children under 14 years old. For full prescribing information, please refer to the
summary of product characteristics.20 †The maximum dose per week of ferric carboxymaltose is 1000 mg. Two dosing sessions are required in case
the patient needs >1000 mg ferric carboxymaltose.20 Algorithms adapted from Cappellini et al.1 and McDonagh and Macdougall.7 Hb, haemoglobin;
i.v., intravenous; NYHA, New York Heart Association; TSAT, transferrin saturation.
Table 2 Summary of absolute and functional iron deﬁciency in CHF6,21,22
Absolute iron deﬁciency Functional iron deﬁciency
Aetiology Decreased iron intake and GI
absorption; increased blood
loss
Pro-inﬂammatory mediators, e.g. interleukin-6 in chronic inﬂammation,
trigger up-regulation of the hepatic hormone hepcidin and subsequent
internalization and degradation of the iron transporter ferroportin.
This in turn causes iron sequestration in enterocytes and
reticuloendothelial cellsa
Iron stores Depleted Normal or abundant but iron unavailable
Iron availability Decreased Decreased
Serum ferritin levels <100 μg/Lb >100 to <300 μg/L
TSAT levels < 20% < 20%
CHF, chronic heart failure; GI, gastrointestinal; TSAT, transferrin saturation.
aThe role of locally produced hepcidin in CHF is still unknown.6
bIn the absence of a chronic inﬂammatory disease state, serum ferritin levels <30 μg/L indicate absolute iron deﬁciency.23,24
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of iron to iron-utilizing tissues, despite seemingly
sufﬁcient body iron stores [indicated by low TSAT values
(< 20%)].6,21,28 This is a result of chronic inﬂammation,
which triggers regulatory mechanisms leading to iron
sequestration in enterocytes and reticuloendothelial cells
(Table 2).29–31 Importantly, for both forms of iron deﬁciency
(absolute and functional), the treatment is the same (iron
replenishment therapy).1,6,18,21 Both types of iron deﬁciency
may occur without concomitant presence of anaemia; how-
ever, with advancing severity of iron deﬁciency, overt anae-
mia may develop because of a lack of iron in utilizing
tissues. In the current manuscript, ‘iron deﬁciency’ refers
to both types unless otherwise stated.
In order to encompass iron deﬁciency in chronic inﬂamma-
tory conditions such as CHF, the following single consensus
diagnostic threshold criterion has been proposed: serum fer-
ritin <100 μg/L or TSAT < 20% (if serum ferritin is between
100 and <300 μg/L, TSAT < 20% will be required to conﬁrm
iron deﬁciency).1
Treatment and management of iron
deﬁciency in chronic heart failure
The clinical case
Iron deﬁciency anaemia was diagnosed (other causes of
anaemia and occult blood loss accounting for absolute iron
deﬁciency were excluded; Figure 1A). The patient was subse-
quently treated with i.v. iron as shown in the diagnostic algo-
rithm (Figure 1A).1 The repletion dose for this patient,
1000 mg ferric carboxymaltose, was calculated according to
her weight (66 kg) and Hb levels (11.9 g/dL; Figure 1B). There
was no change in her heart failure treatment.
Ferric carboxymaltose was administered with an infusion
of 100 mL normal saline (a maximum of 250 mL diluting vol-
ume is allowed for this dose; Tables 3 and 4) in one session
over 15 min, as outlined in Tables 3 and 4. A slow non-diluted
bolus injection of i.v. ferric carboxymaltose could also have
Table 3 Practical guidance for the treatment of iron deﬁciency in patients with CHF18,20
In whom and when?
Indications
1. Intravenous iron, ferric carboxymaltose, should be considered in symptomatic patients with chronic systolic HFrEF or heart failure with
LVEF < 45% and iron deﬁciency (2016 ESC guideline recommendations: Class of Recommendation IIa, Level of Evidence A).
2. Iron deﬁciency can be diagnosed based on the following thresholds: serum ferritin <100 μg/L or TSAT < 20% (if serum ferritin 100–300 μg/L,
a TSAT test will be required to diagnose iron deﬁciency).
Contraindications
1. Hypersensitivity to the active substance, ferric carboxymaltose, or any of its excipients.
2. Known serious hypersensitivity to other parenteral iron products.
3. Anaemia not attributed to iron deﬁciency, e.g. other microcytic anaemia.
4. Evidence of iron overload or disturbances in the utilization of iron.
Cautions/seek specialist advice
1. Use with caution in patients with acute or chronic infection; treatment with ferric carboxymaltose should be stopped in patients with
ongoing bacteraemia.
2. Patients with known drug allergies, including those with a history of severe asthma, eczema, or other atopic allergies, may be at increased
risk of hypersensitivity reaction.
3. Increased risk of hypersensitivity reactions to parenteral iron complexes in patients with immune or inﬂammatory conditions (e.g. systemic
lupus erythematosus and rheumatoid arthritis).
4. No clinical evidence for ferric carboxymaltose in patients with HFpEF (LVEF > 50%) or LVEF > 45%.
5. Ferric carboxymaltose has not been evaluated in patients with Hb level >15 g/dL.
Where?
1. Ferric carboxymaltose can be administered in the hospital or community setting, where staff are trained and equipped to monitor and
manage hypersensitivity reactions.
How to use?
1. Determination of the initial iron need is calculated based on body weight and Hb levels (see dosing table in Figure 1B).
2. Ferric carboxymaltose may be given intravenously as an undiluted bolus injection or an infusion that requires dilution. If given as an infusion,
it should not be overdiluted (see dilution plan in Table 4).
3. The maximum recommended cumulative dose of ferric carboxymaltose is 1000 mg of iron (i.e. 20 mL ferric carboxymaltose)/week.
Monitoring
1. Following replacement, iron status should be re-evaluated in 12 weeks and further iron repletion provided as needed, as well as evaluation
for blood loss as indicated.
2. Iron status should also be rechecked if patients remain symptomatic despite receiving optimal background heart failure medications, or
in the event of Hb levels decreasing.
3. In patients with stable CHF, iron status should be checked as part of the routine laboratory test assessments (at least once a year).
CHF, chronic heart failure; ESC, European Society of Cardiology; Hb, haemoglobin; HFpEF, heart failure with preserved ejection fraction;
HFrEF, heart failure with reduced ejection fraction; LVEF, left ventricular ejection fraction; TSAT, transferrin saturation.
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been feasible in this patient following the treatment scheme
suggested in the CONFIRM-HF study.15
At the 12 week follow-up assessment, the patient’s status
had improved to functional class NYHA II. In accordance with
the guidelines, blood parameter measurements were
reassessed, and the patient was no longer anaemic (Hb:
12.3 g/dL), but she was still iron deﬁcient (serum ferritin:
87 μg/L; TSAT: 19%; Figure 2). In line with the diagnostic
and treatment algorithms (Figure 1), a further dose of i.v. fer-
ric carboxymaltose (500 mg) was administered via infusion.
At the 24 week follow-up assessment, the patient’s
symptoms had improved to NYHA I, with no decompensation
or hospitalization. However, she was still iron deﬁcient (serum
ferritin: 91 μg/L; TSAT: 28%; Figure 2) and required a further
500 mg dose of ferric carboxymaltose. This time, treatment
was administered undiluted over 6 min in an i.v. bolus
(Tables 3 and 4).
After this repeated iron replenishment, the patient was no
longer iron deﬁcient, and her CHF symptoms remained stable
(NYHA I at Week 36), with no further hospitalizations or de-
compensation episodes. Ferric carboxymaltose was well tol-
erated, and no adverse events were reported throughout
her treatment period.
The patient’s iron parameters should be reassessed within
3 to 6 months to allow for the prompt detection and appro-
priate management of iron deﬁciency should it reoccur.
Treatment options and guideline
recommendations
Treatment with i.v. ferric carboxymaltose is the correct
evidence-based treatment for this patient, based on data
from randomized controlled trials. The efﬁcacy of i.v.
ferric carboxymaltose has been extensively examined in
symptomatic iron-deﬁcient patients with CHF (HFrEF;
LVEF ≤ 45%).2–4,8–15 In the FAIR-HF study, iron-deﬁcient
CHF patients treated with i.v. ferric carboxymaltose experi-
enced signiﬁcant improvements in symptoms compared
with those receiving placebo at Week 24 [measured using
the patient global assessment (P < 0.001), along with im-
provements in NYHA class (P < 0.001)] and in exercise ca-
pacity as measured by the 6 min walk test (6MWT;
P < 0.001 at Weeks 4, 12, and 24).13 These ﬁndings are
further supported by the 52 week CONFIRM-HF study ex-
amining i.v. ferric carboxymaltose vs. placebo (6MWT at
Table 4 Dilution plan and administration time for i.v. ferric carboxymaltose infusion20
Volume of ferric
carboxymaltose
required (mL)
Equivalent iron
dose (mg)
Maximum amount
of sterile 0.9% m/V sodium
chloride solution (mL)
Minimum administration
time (min)
2–4a 100–200 50 —
>4–10b >200–500 100 6
>10–20 >500–1000 250 15
i.v., intravenous.
Notably, there are two possible modes of administration: (i) infusion using the dilution guidelines indicated in this table and (ii) injection
(up to 1000 mg iron) without dilution and over a shorter administration time.20
Injection administration rates:
aNo minimal prescribed time.
b100 mg iron/min.
Figure 2 Patient’s changes in serum ferritin, transferrin saturation (TSAT), and haemoglobin (Hb) levels over time.
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Week 24: P = 0.002; 6MWT at Week 52: P < 0.001; patient
global assessment: P = 0.001; and NYHA improvement:
P < 0.001).15 Furthermore, signiﬁcant beneﬁts were also
observed in QoL questionnaires in the same patients in
the FAIR-HF (at Weeks 4, 12, and 24: P < 0.001) and
CONFIRM-HF (at Week 52: P < 0.05) studies.15,32 In the
most recent EFFECT-HF study, treatment with i.v. ferric
carboxymaltose in patients with HFrEF and iron deﬁciency
increased iron stores. A favourable effect on peak volume
of oxygen (VO2) was observed in the primary analysis in
patients treated with i.v. ferric carboxymaltose compared
with standard of care (including oral iron), yet the authors
concluded that this effect was sensitive to the imputation
strategy utilized in this unblinded trial.14 A recent individual
patient data meta-analysis revealed a signiﬁcant decrease
in the composite of recurrent heart failure hospitalizations
and cardiovascular mortality (rate ratio 0.53, 95%
conﬁdence interval 0.33–0.86; P = 0.011) when patients
were treated with i.v. ferric carboxymaltose compared with
placebo.10 Although several i.v. iron preparations are
available, only ferric carboxymaltose has been studied in
patients with CHF.33 Accordingly, the 2016 ESC guidelines
speciﬁcally recommend ferric carboxymaltose for HFrEF
(LVEF ≤ 45%; Class of Recommendation IIa, Level of
Evidence A).18
Oral iron is repeatedly discussed as a treatment option in
the CHF context; however, the impaired enteral absorption
in this setting and other conditions characterized by immune
activation is considered to render oral iron administration
ineffective. In the 16 week, randomized, prospective,
IRONOUT HF study conducted in a similar population of
HFrEF and iron-deﬁcient patients, high-dose oral iron treat-
ment was ineffective at correcting iron deﬁciency and did
not improve peak VO2 (oral iron vs. placebo: P = 0.46) or
other functional measures such as the 6MWT (P = 0.19),
N-terminal pro-B-type natriuretic peptide (P = 0.48), and
Kansas City Cardiomyopathy Questionnaire clinical summary
scores (P = 0.57).34 Owing to the lack of efﬁcacy of oral iron
in CHF, unfavourable GI adverse event proﬁle, and low
absorption in inﬂammatory conditions such as CHF,35,36
current guidelines do not recommend oral iron for the
treatment of iron deﬁciency in CHF.18
Practical considerations
Intravenous ferric carboxymaltose is generally easy to
deliver and well tolerated. It can be administered intrave-
nously as an infusion or injection, and to ensure that the full
dose is given, the line should be ﬂushed with normal saline
(Table 3). Dilutions are not required, and administration
time is shorter when i.v. ferric carboxymaltose is
administered via injection vs. infusion (Table 4). For
infusions, ferric carboxymaltose (500–1000 mg doses) can
be diluted using a small bag of normal saline (50–100 mL,
maximum 250 mL; Table 4). In contrast to older i.v. iron
complexes, hypersensitivity reactions related to ferric
carboxymaltose are rare (≥1/1000 to <1/100).20 However,
equipment for the evaluation and treatment of potential
hypersensitivity reactions should be available within the
facility (Table 3).
Intravenous ferric carboxymaltose administration can be
provided on an ambulatory basis (e.g. in a day hospital). In
the case study example, only one dose of 1000 mg i.v. ferric
carboxymaltose was required for the initial correction of iron
deﬁciency. However, in some cases, depending on Hb levels
and body weight, two doses of i.v. ferric carboxymaltose
may be required over two sessions (Table 3); in this situation,
the second dose would need to be administered 1 week after
the initial dose.20
Follow-up management of iron deﬁciency in
chronic heart failure
Following initial ferric carboxymaltose administration, physicians
are recommended to follow up with their patients at 12 weeks
to evaluate the clinical and haematological response (serum
ferritin, TSAT, and Hb; Figure 1B and Table 3), even if patients
are receiving optimal heart failure treatment.
Conclusions
Iron deﬁciency alone, even in the absence of anaemia, is a com-
mon co-morbidity in patients with CHF. If left untreated, iron
deﬁciency can account for poor clinical outcomes, as illustrated
in the case study patient who was diagnosed when guidelines
were unavailable. The case study provides a practical example
of the diagnosis and management of iron deﬁciency in a patient
with HFrEF, demonstrating the application of the current ESC
guidelines in a clinical context. In support of clinical evidence
and guidelines, the case study shows that treatment with i.v.
ferric carboxymaltose improves clinical symptoms (from NYHA
III to NYHA I; i.e. exercise capacity and QoL) with no adverse
events. Furthermore, i.v. ferric carboxymaltose could provide
cost-effective savings as there was less intervention, that is,
no hospitalizations or decompensations. Despite a solid
evidence base and guideline recommendation, iron deﬁciency
currently remains underdiagnosed and undertreated. The
2016 ESC guidelines for the diagnosis and treatment of acute
and chronic heart failure recommend evaluating the iron
status of all newly diagnosed CHF patients and consideration
of i.v. ferric carboxymaltose for those patients with iron
deﬁciency to alleviate CHF symptoms and improve exercise
capacity and QoL.
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